CN103349669A - Malic acid-containing composite dialysis preparation and preparation method thereof - Google Patents
Malic acid-containing composite dialysis preparation and preparation method thereof Download PDFInfo
- Publication number
- CN103349669A CN103349669A CN2013101091361A CN201310109136A CN103349669A CN 103349669 A CN103349669 A CN 103349669A CN 2013101091361 A CN2013101091361 A CN 2013101091361A CN 201310109136 A CN201310109136 A CN 201310109136A CN 103349669 A CN103349669 A CN 103349669A
- Authority
- CN
- China
- Prior art keywords
- agent
- dialysis
- preparation
- acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000502 dialysis Methods 0.000 title claims abstract description 67
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 235000011090 malic acid Nutrition 0.000 title claims abstract description 35
- 239000001630 malic acid Substances 0.000 title claims abstract description 34
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 title claims abstract description 28
- 239000002131 composite material Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 71
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 50
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 30
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 28
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 28
- 239000011780 sodium chloride Substances 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 15
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000001110 calcium chloride Substances 0.000 claims abstract description 14
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 14
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 14
- 239000001103 potassium chloride Substances 0.000 claims abstract description 14
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 12
- 239000008103 glucose Substances 0.000 claims abstract description 12
- 229940049920 malate Drugs 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 41
- 239000000243 solution Substances 0.000 claims description 36
- 235000002639 sodium chloride Nutrition 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000012856 packing Methods 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 15
- 239000006174 pH buffer Substances 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- -1 malic acid compound Chemical class 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000012982 microporous membrane Substances 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000000385 dialysis solution Substances 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 4
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 239000001384 succinic acid Substances 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 27
- 230000009467 reduction Effects 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 102000003390 tumor necrosis factor Human genes 0.000 abstract description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 2
- 239000011574 phosphorus Substances 0.000 abstract description 2
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 2
- 239000006172 buffering agent Substances 0.000 abstract 1
- 230000007969 cellular immunity Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 238000001631 haemodialysis Methods 0.000 description 9
- 230000000322 hemodialysis Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000000227 grinding Methods 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 3
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000013155 cardiography Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a malic acid-containing composite dialysis preparation and a preparation method thereof. The composite dialysis preparation comprises an agent A and an agent B, wherein raw materials of the agent A comprise, by weight, 10-30 parts of sodium chloride, 0-2 parts of potassium chloride, 0.5-2 parts of calcium chloride, 0.2-0.5 part of magnesium chloride, 0.1-8 parts of malic acid, 0-8 parts of malate, 0-5 parts of glucose, and 0-8 parts of a pH value buffering agent, and a raw material of the agent B comprises, by weight, 5-10 parts of sodium bicarbonate. With the present invention, special treatment effects are provided in the fields of cellular immunity improvement, myocardial coordination improvement, tumor necrosis factor reduction, serum phosphorus content reduction, CO2CP increase, dialysis imbalance disorder treatment and the like.
Description
Technical field
The present invention relates to the blood purification treatment field, relate in particular to a kind of compound dialysis preparation of malic acid and preparation method thereof that contains.
Background technology
Hemodialysis is a kind of method for the treatment of chronic renal insufficiency.Be by dialysis machine patient's blood to be derived externally, finish transmission to solute in the blood and water by blood purification technology, remove creatinine in the patient body, the refuses such as blood urea nitrogen.Remove moisture, improve electrolyte concentration etc.Blood after will purifying is again led the Huis' body.Reach the purpose for the treatment of.
The hemodialysis technology in clinical practice decades.But some not clear complication claim again the hemodialysis unbalanced syndrome, are still perplexing us such as nauseating, vomiting, headache, fatigue, uneasiness, hypertension, hypotension even heart failure etc.In case occur, clinically generally only can adopt symptomatic treatment; As finishing in advance hemodialysis, high sodium chloride or Glucose Liquid and the mannitol etc. of oozing of intravenous drip, so far not yet effective control method.
Summary of the invention
The invention provides a kind of compound dialysis preparation of malic acid and preparation method thereof that contains, be intended to solve the problem that existing hemodialysis technology can not effectively be controlled complication.
The present invention addresses the above problem with following technical scheme, the invention provides a kind of compound dialysis powder preparation of malic acid that contains, and described compound dialysis powder preparation comprises A agent and B agent.Wherein:
Described A agent raw material by weight component is sodium chloride 10-30, potassium chloride 0-2, calcium chloride 0.5-2, magnesium chloride 0.2-0.5, hydroxyl succinic acid 0.1-8, malate 0-8, glucose 0-5, pH buffer agent 0-8;
Described B agent raw material by weight component is sodium bicarbonate 5-10, but or sodium chloride-containing 0-5.
Wherein, hydroxyl succinic acid has another name called malic acid.
The present invention also provides a kind of preparation method that contains the compound dialysis powder preparation of malic acid, and described method comprises the steps:
The electrolyte of more than one in the group that sodium chloride, potassium chloride, calcium chloride, magnesium chloride are formed sieves after crushed;
More than one Organic substances in the group of the compositions such as hydroxyl succinic acid and/or its salt, glucose, pH buffer agent are sieved after crushed, and each the component mix homogeneously after will sieving again is sub-packed in the packing container to get the A agent;
By sodium bicarbonate or also contain sodium chloride through pulverize, sieve, mix homogeneously be sub-packed in packing in the molten device the B agent.
The present invention also provides a kind of malic acid compound dialysate preparation that contains, and it is characterized in that, described compound dialysate preparation comprises A concentrated solution and B concentrated solution.Wherein:
Described A concentrated solution be raw material by weight component be sodium chloride 10-30, potassium chloride 0-2, calcium chloride 0.5-2, magnesium chloride 0.2-0.5, hydroxyl succinic acid 0.1-8, malate 0-8, glucose 0-5, pH buffer agent 0-8, be mixed with 1000ml unit's concentrated solution, pH2.0-7.8 with water for dialysis.
Described B concentrated solution be raw material by weight component be sodium bicarbonate 5-10, be mixed with 1000ml concentrate, pH6.8-9 with water-dialyzing.
The present invention also provides a kind of preparation method that contains malic acid compound dialysate preparation, it is characterized in that, described method comprises the steps:
Get described A agent and B agent, use respectively without the dissolving of thermal source water for dialysis, pH2.0-7.8 is adjusted in described A agent, and pH6.8-9.0 is adjusted in described B agent;
A agent after the described dissolving, B agent respectively through filtering with microporous membrane, are used the ultrafilter membrane separating and filtering again, be sub-packed in asepticly, in the apyrogenic container, get A concentrated solution and B concentrated solution.
When clinical use, the dialysis solution that A, B liquid are mixed mutually and add that water for dialysis is made into etc. and ooze by the ratio of dialysis machine requirement is for the patient.
The present invention has obtained special therapeutic effect at aspects such as improving cellular immunization and myocardium harmony, minimizing tumor necrosis factor, reduction serum paraoxonase content, raising CO2CP and the unbalance disease for the treatment of dialysis.
The specific embodiment
In order to make purpose of the present invention, technical scheme and advantage clearer, below in conjunction with embodiment, the present invention is further elaborated.Should be appreciated that specific embodiment described herein only in order to explain the present invention, is not intended to limit the present invention.
Embodiment one
The embodiment of the invention provides a kind of compound dialysis powder preparation of malic acid that contains, and is comprised of A agent and the B agent of packing.Wherein:
The A agent is mainly made by following weight portion component combination: sodium chloride 10-30, potassium chloride 0-2, calcium chloride 0.5-2, magnesium chloride 0.2-0.5, hydroxyl succinic acid (having another name called malic acid) 0.1-8, malate 0-8, glucose 0-5, pH buffer agent (comprising hydrochloric acid, acetic acid, citric acid, lactic acid, aminoacid and/or its salt) 0-8.
The B agent is mainly made by following weight portion material combination: sodium bicarbonate 5-10 or further sodium chloride-containing 0-5 also.
In embodiments of the present invention, A agent, B agent raw material are preferably following parts by weight of component:
The A agent is mainly made by following weight portion material combination: sodium chloride 21.0, potassium chloride 1.0, calcium chloride 1.4, magnesium chloride 0.7, malic acid 4.0, malate 1.0, glucose 0.5, pH buffer agent (comprising hydrochloric acid and acetic acid, citric acid, lactic acid, aminoacid and/or its salt) 1.0.
The B agent is mainly made by following weight portion material combination: sodium bicarbonate 8.0 or further sodium chloride-containing 3.3 also.This compound dialysis powder preparation is preferably the 60-100 order through pulverizing, sieving, and especially 80 orders are sealed in packing container.
When clinical use, A, B agent are added respectively reverse osmosis water dissolving, be prepared into compound dialysis A concentrated solution, the B concentrated solution mixes by the ratio of the required mutually again, the compound dialysate that oozes such as is diluted to for the patient.
In embodiments of the present invention, the preparation method of compound dialysis powder preparation, details are as follows:
Get in proportion described sodium chloride, potassium chloride, calcium chloride, magnesium chloride, malic acid, malate, glucose, pH buffer agent.Mixing, be crushed to fine powder, preferentially be crushed to the 60-100 order, especially is 80 orders, and with above-mentioned fine powder mix homogeneously, packing is the A agent; Other gets sodium bicarbonate or/and sodium chloride powder is broken to fine powder, preferentially is crushed to the 60-100 order, especially is 80 orders, and packing is compound dialysis powder B agent formulation.
Embodiment two
The embodiment of the invention two provides a kind of concentrated solution preparation that contains the malic acid compound dialysate, is comprised of A concentrated solution and the B concentrated solution of packing.Wherein:
The A concentrated solution is mainly made by following weight portion raw material components: A agent raw material components is mixed with 1000ml unit's concentrated solution, pH2.0-7.8 with water for dialysis.
The B concentrated solution is mainly made by following weight portion raw material components: B agent raw material components, be mixed with the 1000ml concentrate with water-dialyzing, and pH6.8-9, described A concentrated solution, the B concentrated solution is preferably pH7.1.The A of this compound dialysate, B concentrated solution, in coarse filtration, fine straining, ultrafiltration were sealed in respectively independently container, the dialysis solution that when clinical use A, B liquid is mixed mutually and add that water for dialysis is made into etc. and ooze by the ratio of dialysis machine requirement was for the patient.
In embodiments of the present invention, the preparation method of compound dialysis powder preparation, details are as follows:
Get the A agent of above-mentioned preparation, aseptic, the pyrogen-free water for dialysis through the reverse osmosis preparation is further used respectively in the B agent, be mixed with the 1000ml concentrated solution, check pH value, regulate with the pH buffer agent in case of necessity, preferential pH7.1, through micro-pore-film filtration, the ultrafilter membrane separating and filtering is in the filling and package container, make respectively the A concentrated solution, the B concentrated solution.The A of independent packaging, B concentrated solution form the concentrated solution preparation of compound dialysate.
Embodiment three
In embodiments of the present invention, contain the compound dialysis A of malic acid agent, B agent assembly packaging is:
A agent: get sodium chloride 210.7g, potassium chloride 5.2g, calcium chloride 7.7g, magnesium chloride 3.6g co-grinding to 60 order; Get malic acid 20g, malate 5.8g, pH buffer agent 2.5g, co-grinding to 80 order remixes said components, is sub-packed in the aseptic packing container.Improving dissolution velocity, in order to the dialysis solution that oozes such as be mixed with during clinical use; B agent: get sodium bicarbonate 80g, pulverized 100 mesh sieves, be sub-packed in the aseptic packing container.When clinical use, A, B agent are added respectively water for dialysis are dissolved to 1000ml, make compound dialysis A concentrated solution, the B concentrated solution, more by the ratio of the required mutually the solution that oozes such as mixed diluting one-tenth for clinical.
Embodiment four
In embodiments of the present invention, contain the compound dialysis A of malic acid agent, B liquid assembly packaging is:
The A agent; Get sodium chloride 214g, potassium chloride 5.2g, calcium chloride 6.4g, magnesium chloride 3.6g co-grinding to 80 order; Get glucose 1.5g, malic acid 20g, malate 5.8g, pH buffer agent 3.0g, co-grinding to 80 order remixes said components, is sub-packed in the aseptic packing container.Improving dissolution velocity, ooze dialysis solution in order to be mixed with during clinical use etc.; B liquid: get sodium bicarbonate 80g, pulverized 100 mesh sieves, adding is dissolved to 1000ml without the thermal source water for dialysis, behind the 0.22u filtering with microporous membrane.Use the ultrafilter membrane separating and filtering, be sub-packed in aseptic, the apyrogenic packing container.In the time of before clinical use, the A agent is added water for dialysis is dissolved to 1000ml and makes compound dialysis A liquid, again with B liquid on request the mutual mixed diluting of ratio become isosmotic solution for clinical.
Embodiment five
In embodiments of the present invention, contain the compound dialysis A of malic acid liquid, B agent assembly packaging is:
A liquid: get sodium chloride 210.7g, potassium chloride 5.2g, calcium chloride 67.7g, magnesium chloride 3.6g co-grinding to 60 order, get malic acid and/or its salt 24.8g, co-grinding to 60 order, said components is dissolved to 1000ml with water for dialysis, in case of necessity again with behind lactic acid or its salt adjustment pH2.4 usefulness 0.22u filtering with microporous membrane.Use the ultrafilter membrane separating and filtering, be sub-packed in aseptic, the apyrogenic packing container.B agent: get sodium bicarbonate 67g, sodium chloride 33g, pulverized 100 mesh sieves, be sub-packed in the aseptic packing container.When clinical use, the B agent is dissolved to 1000mL with water for dialysis makes B liquid, again with A liquid on request the mutual mixed diluting of ratio the compound dialysate that oozes such as become for clinical.
Embodiment six
In embodiments of the present invention, contain the compound dialysis A of malic acid concentrated solution, B concentrated solution assembly packaging is:
A liquid: get sodium chloride 214g, potassium chloride 5.2g, calcium chloride 6.7g, magnesium chloride 3.6g co-grinding to 60 order, get malic acid and/or its salt 25.8g, glucose 1.5g, pH buffer agent 3.0g, co-grinding to 60 order, said components is dissolved to 1000ml with water for dialysis, adjust pH2.4 with aminoacid and/or its salt in case of necessity, behind the 0.22u filtering with microporous membrane.Use the ultrafilter membrane separating and filtering, be sub-packed in aseptic, the apyrogenic packing container.
B liquid is got 70g, sodium chloride 30g, pulverizes 80 orders and sieves, after the adding water for dialysis is dissolved to 1000ml usefulness 0.22u filtering with microporous membrane after mixing.Use again the ultrafilter membrane separating and filtering, be sub-packed in aseptic, the apyrogenic packing container.With A liquid, B liquid on request ratio mixed diluting becomes the compound dialysate of equivalent for clinical in clinical use.
Compound dialysis powder/liquid in the embodiment of the invention is through result's confirmation of Clinical control experiment, and to correcting electrolyte balance and acidosis, cleaning serum urea nitrogen and creatinine always effectively are 100%.This product is not only effective equally with reference substance aspect above-mentioned treatment, has also obtained special therapeutic effect at aspects such as improving cellular immunization and myocardium harmony, minimizing tumor necrosis factor, reduction serum paraoxonase content, raising CO2CP and the unbalance disease for the treatment of dialysis.That traditional dialysis treatment institute is inaccessiable.
In embodiments of the present invention, the toxicity of compound dialysis powder/liquid and clinical trial situation, details are as follows:
One. the clinical relatively mool/L of sample main component that uses
Two. acute toxicity test:
20 of Kunming mouses, body weight 18-22g compound dialysate dilute 35 times with water for injection in proportion, tail vein multiple injection, and maximum tolerated dose＞200mL/kg observes seven days no abnormality seens after the injection.
Three. clinical observation result
1. the improvement situation of two groups of every biochemical indicators in patient treatment front and back sees Table 1,2.Wherein, table 1 is for dialysing front two groups of test indexes relatively, and table 2 compares n=30 for two groups of test indexes after dialysing.
Table 1
Table 2
All have clear improvement after two groups of every biochemical indicator dialysis of patient, but experimental group and matched group relatively improve Ca
2+With CO2CP significantly (P＜0.05), and to the clearance rate of serum paraoxonase also than matched group significantly (P＜0.05).
2. the surrounding blood lymphocyte group measures.
Before and after two groups of treatments, surrounding blood lymphocyte group measurement result comparative result sees Table 3 (X ± SX) (%).
Table 3
CD after the matched group dialysis
+4 decline highly significants (P＜0.001) and CD8 be without significant change, and CP4 is without change after the experimental group dialysis, and CD8 descends significantly (P＜0.05), so the CD4/CD8 matched group descends, and experimental group raises, and significant difference P＜0.05 is relatively arranged between two groups
3. IL-2 after two groups of treatments, the variation of TNFa relatively sees Table 4, (the ug/L of X ± SX).
Table 4
All raise to some extent behind two groups of TNF horizontal stretchers, and experimental group rising degree is lower, the two has highly significant difference P＜0.001, and two groups all decrease after the IL-2 treatment, and matched group reduces more obvious, and two groups have very significantly difference.
4. treat rear ultrasoundcardiograms for two groups, the result of MGBP relatively sees Table 5.
Table 5
Two groups of LVEF, right ventricle's ejection fraction (RVEF), peak, left chamber ejection rate (PER) is lower than normally, but no significant difference between two groups, phase angular travel (PSH) matched group is obviously greater than experimental group (P＜0.05).
5. two groups for the treatment of hemodialysis unbalanced syndrome clinical effectivenesses relatively see Table 6.
Table 6
Compound dialysis powder/liquid of the present invention has significant effect P＜0.05 to treatment hemodialysis unbalanced syndrome
Relatively having the following advantages of the comprehensive above-mentioned clinical effectiveness of the embodiment of the invention;
1. the compound dialysis powder/liquid of the embodiment of the invention not only can effectively be corrected electrolyte disturbance, remove the micromolecule toxin such as BUN, Cr in the blood, and significantly be better than traditional hemodialysis in the low calcium of correction, high phosphorus and correction metabolic acidosis (CO2CP).
2. the compound dialysis powder/liquid of the embodiment of the invention can effectively improve cellular immune function, and behind table 2 clinical blood dialysis treatment, traditional treatment is take decline CD4 as main, and experimental group to be to reduce CD8 as main, and namely the former CD4/CD8 descends, and the latter rises.IL-2 is the cytokine that t helper cell produces in addition, and it can promote increment and the differentiation of T lymphocyte and bone-marrow-derived lymphocyte, and chronic renal patient reduces mostly, and its reason it be unclear that.Above-mentioned clinical effectiveness shows: experimental group increases significantly than matched group IL-2 behind the dialysis treatment.Can point out after compound dialysis powder/liquid treatment from above CD4/CD8 ratio and IL-2 index, it is that traditional dialysis treatment is incomparable that patient's cellular immune function is improved.
Ultrasonic cardiography (MGBP) observe reflecting myocardium shrink harmony index PSH (as showing that greater than 70 ° cardiac muscle can not synchronous, myocardium inaccurate coordination) traditional treatment PSH be 81.64 ° obviously greater than 70 °.PSH is normal in compound dialysis powder of the present invention/liquid treatment, points out product of the present invention that heart is had protective effect.
4. important inflammatory cytokine TNF can activate synthesized acute to phase albumen, and the oxygen reduction free radical promotes fat, muscle, connective tissue decomposition etc.Clinically show as heating.The discomforts such as hypotension.Above-mentioned clinical observation shows the TNFa value of experimental group, the result who is lower than the comprehensive above-mentioned clinical indexes of matched group P＜0.001. of highly significant after the treatment, that has embodied clinical treatment hemodialysis unbalanced syndrome the results are shown in Table 5, shows compound dialysis powder of the present invention/fluid component reasonable mixture ratio.Clinical practice has reached the traditional treatment special medical effect that is beyond one's reach.
5. for fear of the imbalance of Renal Failure Patients internal metabolism process, alleviate the kidney burden, the patient all is subject to strict control at daily life and diet style.This has brought a lot of inconvenience for undoubtedly patient's treatment.And utilize the method for dialysis treatment, make medicine (as; Malic acids etc.) be transported to by semipermeable membrane and bring into play therapeutical effect in the body, be one has the administering mode of creating meaning very much.
6. the compound dialysis powder/liquid of the present invention preparation, solute effect is good, powder/liquid good stability.Apyrogeneity, without microgranule, various composition proportion are accurate.Use raw material all to meet the Pharmacopoeia of People's Republic of China standard.
Claims (10)
1. one kind contains the compound dialysis powder preparation of malic acid, it is characterized in that, described compound dialysis powder preparation comprises A agent and B agent.Wherein:
Described A agent raw material by weight component is sodium chloride 10-30, potassium chloride 0-2, calcium chloride 0.5-2, magnesium chloride 0.2-0.5, hydroxyl succinic acid 0.1-8, malate 0-8, glucose 0-5, pH buffer agent 0-8;
Described B agent raw material by weight component is sodium bicarbonate 5-10.
2. the compound dialysis powder preparation of malic acid that contains as claimed in claim 1 is characterized in that, but described B agent raw material by weight component be sodium bicarbonate 5-10 or sodium chloride-containing 0-5.
3. the compound dialysis powder preparation of malic acid that contains as claimed in claim 1 is characterized in that, described hydroxyl succinic acid can be L-hydroxysuccinic acid and/or DL-hydroxyl succinic acid.
4. the compound dialysis powder preparation of malic acid that contains as claimed in claim 1 is characterized in that, described pH buffer agent is at least a in the group that forms of free hydrochloric acid, acetic acid, citric acid, lactic acid, aminoacid and/or its salt.
5. a preparation method that contains the compound dialysis powder preparation of malic acid is characterized in that, described method comprises the steps:
The electrolyte of more than one in the group that sodium chloride, potassium chloride, calcium chloride, magnesium chloride are formed sieves after crushed;
More than one Organic substances in the group of the compositions such as hydroxyl succinic acid and/or its salt, glucose, pH buffer agent are sieved after crushed, and each the component mix homogeneously after will sieving again is sub-packed in the packing container to get the A agent;
By sodium bicarbonate or also contain sodium chloride through pulverize, sieve, mix homogeneously be sub-packed in packing in the molten device the B agent.
6. one kind contains malic acid compound dialysate preparation, it is characterized in that, described compound dialysate preparation comprises A concentrated solution and B concentrated solution.Wherein:
Described A concentrated solution be raw material by weight component be sodium chloride 10-30, potassium chloride 0-2, calcium chloride 0.5-2, magnesium chloride 0.2-0.5, hydroxyl succinic acid 0.1-8, malate 0-8, glucose 0-5, pH buffer agent 0-8, be mixed with 1000ml unit's concentrated solution, pH2.0-7.8 with water for dialysis.
Described B concentrated solution be raw material by weight component be sodium bicarbonate 5-10, be mixed with 1000ml concentrate, pH6.8-9 with water-dialyzing.
7. the malic acid compound dialysate preparation that contains as claimed in claim 6 is characterized in that, but described B agent raw material by weight component be sodium bicarbonate 5-10 or sodium chloride-containing 0-5.
8. the malic acid compound dialysate preparation that contains as claimed in claim 6 is characterized in that, described hydroxyl succinic acid can be L-hydroxysuccinic acid and/or DL-hydroxyl succinic acid.
9. the malic acid compound dialysate preparation that contains as claimed in claim 1 is characterized in that, described pH buffer agent is at least a in the group that forms of free hydrochloric acid, acetic acid, citric acid, lactic acid, aminoacid and/or its salt.
10. a preparation method that contains malic acid compound dialysate preparation is characterized in that, described method comprises the steps:
Get described A agent and B agent, use respectively without the dissolving of thermal source water for dialysis, pH2.0-7.8 is adjusted in described A agent, and pH6.8-9.0 is adjusted in described B agent;
A agent after the described dissolving, B agent respectively through filtering with microporous membrane, are used the ultrafilter membrane separating and filtering again, be sub-packed in asepticly, in the apyrogenic container, get A concentrated solution and B concentrated solution.
When clinical use, the dialysis solution that A, B liquid are mixed mutually and add that water for dialysis is made into etc. and ooze by the ratio of dialysis machine requirement is for the patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101091361A CN103349669A (en) | 2013-03-29 | 2013-03-29 | Malic acid-containing composite dialysis preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101091361A CN103349669A (en) | 2013-03-29 | 2013-03-29 | Malic acid-containing composite dialysis preparation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103349669A true CN103349669A (en) | 2013-10-16 |
Family
ID=49306148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101091361A Pending CN103349669A (en) | 2013-03-29 | 2013-03-29 | Malic acid-containing composite dialysis preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103349669A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103638526A (en) * | 2013-12-12 | 2014-03-19 | 河北紫薇山制药有限责任公司 | Preparation for purifying blood as well as preparation method and application thereof |
| CN109432123A (en) * | 2018-11-23 | 2019-03-08 | 济南康和医药科技有限公司 | A kind of compound electrolyte glucose injection and preparation method thereof |
| CN110327371A (en) * | 2019-07-15 | 2019-10-15 | 武汉大学 | Sodium bicarbonate ringer's injection and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060182814A1 (en) * | 1994-07-01 | 2006-08-17 | Leo Martis | Biochemically balanced peritoneal dialysis solutions |
| CN1938058A (en) * | 2004-03-30 | 2007-03-28 | 尼普洛株式会社 | Solid pharmaceutical preparation for dialysis |
| CN101366710A (en) * | 2007-08-16 | 2009-02-18 | 北京信东联创生物技术有限公司 | Medicinal composition for haemofiltration or hemodialysis |
| CN101933939A (en) * | 2010-09-01 | 2011-01-05 | 刘思波 | Malic acid bicarbonate external hemodialysis agent |
| CN102370990A (en) * | 2010-08-09 | 2012-03-14 | 俞黎黎 | Blood purification preparation using malic acid as pH conditioning agent, and preparation method and application thereof |
-
2013
- 2013-03-29 CN CN2013101091361A patent/CN103349669A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060182814A1 (en) * | 1994-07-01 | 2006-08-17 | Leo Martis | Biochemically balanced peritoneal dialysis solutions |
| CN1938058A (en) * | 2004-03-30 | 2007-03-28 | 尼普洛株式会社 | Solid pharmaceutical preparation for dialysis |
| CN101366710A (en) * | 2007-08-16 | 2009-02-18 | 北京信东联创生物技术有限公司 | Medicinal composition for haemofiltration or hemodialysis |
| CN102370990A (en) * | 2010-08-09 | 2012-03-14 | 俞黎黎 | Blood purification preparation using malic acid as pH conditioning agent, and preparation method and application thereof |
| CN101933939A (en) * | 2010-09-01 | 2011-01-05 | 刘思波 | Malic acid bicarbonate external hemodialysis agent |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103638526A (en) * | 2013-12-12 | 2014-03-19 | 河北紫薇山制药有限责任公司 | Preparation for purifying blood as well as preparation method and application thereof |
| CN109432123A (en) * | 2018-11-23 | 2019-03-08 | 济南康和医药科技有限公司 | A kind of compound electrolyte glucose injection and preparation method thereof |
| CN109432123B (en) * | 2018-11-23 | 2021-07-20 | 济南康和医药科技有限公司 | Compound electrolyte glucose injection and preparation method thereof |
| CN110327371A (en) * | 2019-07-15 | 2019-10-15 | 武汉大学 | Sodium bicarbonate ringer's injection and preparation method thereof |
| CN110327371B (en) * | 2019-07-15 | 2021-07-06 | 武汉大学 | Sodium bicarbonate Ringer's injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI326597B (en) | Bicarbonate-based solutions for dialysis therapies | |
| US6986905B1 (en) | Pharmaceutical compositions for treating and saving and the method for the preparation thereof | |
| CN103997915B (en) | The nutrition product of interior fat is reduced during for the preoperative stage before bariatric surgery | |
| US20100136140A1 (en) | A use of hypertonic solution composition in manufacturing medicaments for promoting wound healing | |
| CN1777416A (en) | Lactate containing pharmaceutical composition and uses thereof | |
| JP6388475B2 (en) | Peritoneal dialysis solution containing glucose polymer | |
| AU2021399438B2 (en) | Use of mitoxantrone hydrochloride liposome | |
| KR20130062329A (en) | Anti-viral properties of aloe vera and acquired immune deficiency syndrome(aids) treatment | |
| CN103349669A (en) | Malic acid-containing composite dialysis preparation and preparation method thereof | |
| CN1064849C (en) | Medicine for enriching the blood | |
| CN101254316A (en) | A special anticoagulant hemofiltration replacement fluid formula and its preparation method and application | |
| KR102252944B1 (en) | Dialysis composition | |
| US20130197428A1 (en) | Peritoneal Dialysis Method | |
| CA2753498C (en) | Plasma-adapted balanced electrolyte solution | |
| CN109125411A (en) | The full deer horn glue and preparation method thereof for treating osteoporosis | |
| EP2106791A1 (en) | Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation | |
| CN103054961B (en) | Application of Shenkang injection in preparation of medicament for treating chronic renal failure complication or complication caused by dialysis | |
| JPH03135918A (en) | Immune-activating agent | |
| CN102441160B (en) | Thymosin alpha1 medicinal composition and preparation method thereof | |
| KR20230145464A (en) | Drug composition for treating hyperlipidemia and method for producing the same | |
| Saumarez et al. | Neurological decompression sickness treated without recompression | |
| JP2020537689A (en) | Leukocytosis preparations containing A-nor-5α-androstane compounds and their use | |
| CN1557482A (en) | Immune function regulating and tumor resisting natural nutrient | |
| KR20210126515A (en) | Composition for preventing and treating pulmonary hypertension comprising niclosamide | |
| JP2003507334A (en) | Plasma substitute composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131016 |